Keikhaei Niloofar, Heidari Zahra
Department of Endocrinology and Metabolism, Zahedan University of Medical Sciences, Zahedan, Iran.
Med J Islam Repub Iran. 2021 Dec 14;35:166. doi: 10.47176/mjiri.35.166. eCollection 2021.
Thyroid dysfunction is accompanied with significant metabolic alterations that affect body weight, appetite, and energy expenditure, as well as lipid and carbohydrate metabolism. Leptin, an adipokine produced by adipocytes, regulates food intake and energy storage. Thyroid hormones and leptin share some physiological effects. Changes in leptin have been shown in patients with dysfunction of the thyroid; however, the results are contradictory. The aim of this study was to evaluate the circulating levels of leptin in patients with Graves disease (GD) and Hashimoto thyroiditis (HT) before and after normalization of thyroid function compared with the control group. Newly diagnosed adult patients with GD, HT, and healthy euthyroid controls were recruited. Various clinical and biochemical parameters, including thyroid function tests and serum leptin level, were assessed before and after treatment and compared between groups. Data from 56 patients with HT, 54 patients with GD, and 54 healthy controls were analyzed. Serum leptin levels of patients with HT (30.96 ± 3.88 ng/mL) were found to be significantly higher than the controls (22.35 ± 4.72 ng/mL) (p<0.001), whereas patients with Graves had lower serum leptin levels (14 ± 4.54 ng/mL) (p<0.001). In patients with HT, serum leptin levels showed a significant decrease after treatment (31 vs 27 ng/mL; p<0.001), while in patients with GD, leptin increased significantly after treatment (14 vs 17 ng/mL; p<0.001). The present study showed that serum leptin levels increased in patients with HT and decreased in those with GD than the control group. However, after treatment, leptin decreased in the Hashimoto group and increased in the Graves group, although it was still significantly different from the control group.
甲状腺功能障碍伴有显著的代谢改变，这些改变会影响体重、食欲、能量消耗以及脂质和碳水化合物代谢。瘦素是一种由脂肪细胞产生的脂肪因子，可调节食物摄入和能量储存。甲状腺激素和瘦素具有一些共同的生理作用。甲状腺功能障碍患者体内的瘦素水平已有变化报道，但结果相互矛盾。本研究旨在评估格雷夫斯病（GD）和桥本甲状腺炎（HT）患者甲状腺功能正常化前后血清瘦素的循环水平，并与对照组进行比较。招募了新诊断的成年GD患者、HT患者和健康的甲状腺功能正常对照者。在治疗前后评估了各种临床和生化参数，包括甲状腺功能测试和血清瘦素水平，并在组间进行比较。分析了56例HT患者、54例GD患者和54例健康对照者的数据。发现HT患者的血清瘦素水平（30.96±3.88 ng/mL）显著高于对照组（22.35±4.72 ng/mL）（p<0.001），而格雷夫斯病患者的血清瘦素水平较低（14±4.54 ng/mL）（p<0.001）。HT患者治疗后血清瘦素水平显著下降（31 vs 27 ng/mL；p<0.001），而GD患者治疗后瘦素显著升高（14 vs 17 ng/mL；p<0.001）。本研究表明，与对照组相比，HT患者的血清瘦素水平升高，GD患者的血清瘦素水平降低。然而，治疗后，桥本组的瘦素水平下降，格雷夫斯组的瘦素水平升高，尽管仍与对照组有显著差异。
